Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C. Methods: We retrospectively reviewed data for a total of 109 patients with chronic hepatitis C, treated with peginterferon alfa and ribavirin. SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed. Results: Data from 66 genotype 1 patients (60.6%) and 43 genotype 2 or 3 patients (39.4%) among the 109 patients were analyzed. SVR rates for the genotype 1 patients were significantly lower for the stage 3-4 group (32.1%) than the stage 0-2 group (78.9%; P<0.001). SVR rates (92.0% for stage 0-2, 77.8% for stage 3-4, P=0.184) of genotype 2 or 3 patients were not significantly different according to fibrosis stage. Likewise, the frequency of adverse events was not significantly different according to fibrosis stage. Conclusions: Compared to patients without advanced fibrosis, we can anticipate good SVR rates for genotype 2 or 3patients with advanced fibrosis and they did not show an inferior tolerability for peginterferon and ribavirin combination therpy. Our results suggest that active treatment is needed for genotype 2 or 3 patients with advanced fibrosis. (Clin Mol Hepatol 2013;19:148-155)
Abstract
Background/Aims: Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C. Methods: We retrospectively reviewed data for a total of 109 patients with chronic hepatitis C, treated with peginterferon alfa and ribavirin. SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed. Results: Data from 66 genotype 1 patients (60.6%) and 43 genotype 2 or 3 patients (39.4%) among the 109 patients were analyzed. SVR rates for the genotype 1 patients were significantly lower for the stage 3-4 group (32.1%) than the stage 0-2 group (78.9%; P<0.001). SVR rates (92.0% for stage 0-2, 77.8% for stage 3-4, P=0.184) of genotype 2 or 3 patients were not significantly different according to fibrosis stage. Likewise, the frequency of adverse events was not significantly different according to fibrosis stage. Conclusions: Compared to patients without advanced fibrosis, we can anticipate good SVR rates for genotype 2 or 3patients with advanced fibrosis and they did not show an inferior tolerability for peginterferon and ribavirin combination therpy. Our results suggest that active treatment is needed for genotype 2 or 3 patients with advanced fibrosis. (Clin Mol Hepatol 2013;19:148-155)
참고문헌 (22)
- Shepard CW, "Global epidemiology of hepatitis C virus infection", Lancet Infect Dis, 5, pp.558~567 (2005)
- Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
- Bruno S, "Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study", Hepatology, 51, pp.2069~2076 (2010)
- Strader DB, "Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C", Hepatology, 39, pp.1147~1171 (2004)
- Forns X, "Treating hepatitis C in patients with cirrhosis: the effort is worth it", J Hepatol, 52, pp.624~626 (2010)
- 강명주, "우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과", Clinical and Molecular Hepatology, 14(3), pp.318~330 (2008), 대한간학회
- Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
- Pawlotsky JM, "Therapy of hepatitis C: from empiricism to eradication", Hepatology, 43(2 Suppl 1), pp.S207~S220 (2006)
- 이헌주, "한국인 만성 C형간염에서 페그인터페론 알파와 리바비린 또는 인터페론 알파와 리바비린의 병합요법: 치료기간에 따른 성적 비교", Clinical and Molecular Hepatology, 14(1), pp.46~57 (2008), 대한간학회
- Scheuer PJ, "Classification of chronic viral hepatitis: a need for reassessment", J Hepatol, 13, pp.372~374 (1991)
- Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis", Hepatology, 51, pp.388~397 (2010)
- Prati GM, "The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-HCV therapy: A sub-analysis of the MIST study", Hepatology, 50, pp.687A~ (2009)
- Marrache F, "Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis", J Viral Hepat, 12, pp.421~428 (2005)
- Helbling B, "HCV-related advanced fibrosis", cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin, 2006, pp.13, 762~769
- Heathcote EJ, "Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis", N Engl J Med, 343, pp.1673~1680 (2000)
- Pariente A, "Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’: a plea in favor of independent postmarketing evaluations", Eur J Gastroenterol Hepatol, 221, pp.1297~1302 (2010)
- Hepburn MJ, "Differences in treatment outcome for hepatitis C among ethnic groups", Am J Med, 117, pp.163~168 (2004)
- Missiha S, "Khan K; Canadian Pegasys Expanded Access Group. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C", Am J Gastroenterol, 102, pp.2181~2188 (2007)
- Yu ML, "Role of interleukin‐28B polymorphisms in the treatment of hepa titis C virus genotype 2 infection in Asian patients", Hepatology, 53, pp.7~13 (2011)
- 김경훈, "Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis", Clinical and Molecular Hepatology, 17(3), pp.220~225 (2011), 대한간학회
- 윤현아, "만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과", Clinical and Molecular Hepatology, 14(1), pp.36~45 (2008), 대한간학회
- 김정일, "대전과 충청남북도에 거주하는 만성 C형간염 환자에서 페그인터페론 알파 2a와 2b의 초치료 효과 비교", Clinical and Molecular Hepatology, 14(4), pp.493~502 (2008), 대한간학회